| abstract |
Compositions and methods are provided for antibodies that bind specifically to TGF-beta binding proteins. These methods and compositions relate to alteration of mineral density by interfering with the interaction between the TGF-beta binding sclerostin protein and a member of the TGF-beta superfamily, in particular the bone morphogenic protein. Increases in bone mineral density are used in diseases and conditions where low mineral density is a major feature, such as osteopenia, osteoporosis, and bone fractures. |